QQQ   307.80 (+1.39%)
AAPL   154.15 (+1.59%)
MSFT   266.85 (+3.93%)
META   190.72 (+2.50%)
GOOGL   106.58 (+3.58%)
AMZN   100.35 (-1.79%)
TSLA   194.12 (-0.33%)
NVDA   218.91 (+3.80%)
NIO   10.74 (-1.74%)
BABA   104.56 (-0.84%)
AMD   84.65 (+1.16%)
T   19.24 (-1.74%)
F   13.35 (+1.60%)
MU   61.46 (+2.47%)
CGC   2.78 (-5.76%)
GE   81.66 (-0.84%)
DIS   110.96 (+0.99%)
AMC   6.11 (-10.15%)
PFE   43.48 (-0.64%)
PYPL   82.48 (+0.18%)
NFLX   360.00 (-0.41%)
QQQ   307.80 (+1.39%)
AAPL   154.15 (+1.59%)
MSFT   266.85 (+3.93%)
META   190.72 (+2.50%)
GOOGL   106.58 (+3.58%)
AMZN   100.35 (-1.79%)
TSLA   194.12 (-0.33%)
NVDA   218.91 (+3.80%)
NIO   10.74 (-1.74%)
BABA   104.56 (-0.84%)
AMD   84.65 (+1.16%)
T   19.24 (-1.74%)
F   13.35 (+1.60%)
MU   61.46 (+2.47%)
CGC   2.78 (-5.76%)
GE   81.66 (-0.84%)
DIS   110.96 (+0.99%)
AMC   6.11 (-10.15%)
PFE   43.48 (-0.64%)
PYPL   82.48 (+0.18%)
NFLX   360.00 (-0.41%)
QQQ   307.80 (+1.39%)
AAPL   154.15 (+1.59%)
MSFT   266.85 (+3.93%)
META   190.72 (+2.50%)
GOOGL   106.58 (+3.58%)
AMZN   100.35 (-1.79%)
TSLA   194.12 (-0.33%)
NVDA   218.91 (+3.80%)
NIO   10.74 (-1.74%)
BABA   104.56 (-0.84%)
AMD   84.65 (+1.16%)
T   19.24 (-1.74%)
F   13.35 (+1.60%)
MU   61.46 (+2.47%)
CGC   2.78 (-5.76%)
GE   81.66 (-0.84%)
DIS   110.96 (+0.99%)
AMC   6.11 (-10.15%)
PFE   43.48 (-0.64%)
PYPL   82.48 (+0.18%)
NFLX   360.00 (-0.41%)
QQQ   307.80 (+1.39%)
AAPL   154.15 (+1.59%)
MSFT   266.85 (+3.93%)
META   190.72 (+2.50%)
GOOGL   106.58 (+3.58%)
AMZN   100.35 (-1.79%)
TSLA   194.12 (-0.33%)
NVDA   218.91 (+3.80%)
NIO   10.74 (-1.74%)
BABA   104.56 (-0.84%)
AMD   84.65 (+1.16%)
T   19.24 (-1.74%)
F   13.35 (+1.60%)
MU   61.46 (+2.47%)
CGC   2.78 (-5.76%)
GE   81.66 (-0.84%)
DIS   110.96 (+0.99%)
AMC   6.11 (-10.15%)
PFE   43.48 (-0.64%)
PYPL   82.48 (+0.18%)
NFLX   360.00 (-0.41%)
NASDAQ:LSTA

Lisata Therapeutics - LSTA Stock Forecast, Price & News

$3.67
+0.01 (+0.27%)
(As of 02/7/2023 02:47 PM ET)
Add
Compare
Today's Range
$3.63
▼
$3.71
50-Day Range
$2.39
▼
$3.75
52-Week Range
$2.36
▼
$12.30
Volume
8,361 shs
Average Volume
15,446 shs
Market Capitalization
$28.85 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.00

Lisata Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
304.3% Upside
$15.00 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($8.09) to ($3.81) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.13 out of 5 stars

Medical Sector

426th out of 1,029 stocks

Miscellaneous Health & Allied Services, Not Elsewhere Classified Industry

6th out of 9 stocks

See Top Rated MarketRank™ Stocks Here
LSTA stock logo

About Lisata Therapeutics (NASDAQ:LSTA) Stock

Lisata Therapeutics, Inc. develops biopharmaceuticals. It is engaged in the discovery, development, and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. It is designed to modify the tumor microenvironment by activating a novel uptake pathway that allows anti-cancer drugs to penetrate solid tumors more effectively. The company is headquartered in Basking Ridge, NJ.

Receive LSTA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lisata Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

LSTA Stock News Headlines

February 1, 2023 | finance.yahoo.com
Lisata Therapeutics Announces Participation in Upcoming Conferences in February
January 9, 2023 | technews.tmcnet.com
Ractigen Therapeutics Announces the Appointment of Harri Järveläinen as Chief Operating Officer
February 7, 2023 | Wall Street Watch Dogs (Ad)
A gold storm is coming…
“We are in the early stages of a mania – the calm before the storm.”...
January 9, 2023 | finance.yahoo.com
Lisata Therapeutics, Inc. (LSTA)
November 13, 2022 | seekingalpha.com
Lisata Therapeutics, Inc. (LSTA) Q3 2022 Earnings Call Transcript
November 10, 2022 | finance.yahoo.com
Lisata Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
November 7, 2022 | finance.yahoo.com
Lisata Therapeutics Announces Participation in Upcoming Conferences in November 2022
November 3, 2022 | finance.yahoo.com
Lisata Therapeutics to Host Third Quarter 2022 Financial Results Conference Call on Thursday, November 10, 2022, at 4:30 p.m. Eastern Time
February 7, 2023 | Investing Trends (Ad)
Solar Industry at Start of Long Bull Run?
The U.S. solar industry generated nearly $33 billion of private investment in the American economy in 2021 -- and analysts say it looks like the start of a long solar bull market. Leading the way is the just-signed Inflation Reduction Act of 2022. With its generous investment tax credits, the Act is expected to triple U.S. solar energy production over the next 5 years.
October 27, 2022 | seekingalpha.com
LSTA Lisata Therapeutics, Inc.
October 21, 2022 | reuters.com
Lisata Therapeutics Inc
October 19, 2022 | finance.yahoo.com
Lisata Therapeutics’ Director and Scientific Founder of the CendR Platform™ Technology, Erkki Ruoslahti, M.D., Ph.D., Receives 2022 Albert Lasker Basic Medical Research Award
October 19, 2022 | finance.yahoo.com
Lisata Therapeutics Announces Participation in Upcoming Conferences in October 2022
See More Headlines
Receive LSTA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lisata Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

LSTA Company Calendar

Last Earnings
11/10/2022
Today
2/07/2023
Next Earnings (Estimated)
3/28/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Miscellaneous health & allied services, not elsewhere classified
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:LSTA
CUSIP
N/A
CIK
320017
Web
www.caladrius.com
Phone
(908) 842-0100
Fax
646-514-7787
Employees
N/A
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$15.00
High Stock Price Forecast
$15.00
Low Stock Price Forecast
$15.00
Forecasted Upside/Downside
+308.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($12.2279)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-27,470,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-29.53%
Return on Assets
-27.96%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
12.09
Quick Ratio
12.09

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$23.07 per share
Price / Book
0.16

Miscellaneous

Outstanding Shares
7,860,000
Free Float
7,687,000
Market Cap
$28.85 million
Optionable
Not Optionable
Beta
1.10

Key Executives

  • David J. Mazzo
    Chief Executive Officer & Director
  • David Slack
    President, Director & Chief Business Officer
  • James Nisco
    Vice President-Finance & Treasury
  • Gregory S. Berkin
    Chief Information Officer
  • Kristen K. Buck
    Chief Medical Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Institutional Transactions













LSTA Stock - Frequently Asked Questions

Should I buy or sell Lisata Therapeutics stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Lisata Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" LSTA shares.
View LSTA analyst ratings or view top-rated stocks.

What is Lisata Therapeutics' stock price forecast for 2023?

2 brokerages have issued 12-month price objectives for Lisata Therapeutics' shares. Their LSTA share price forecasts range from $15.00 to $15.00. On average, they predict the company's stock price to reach $15.00 in the next year. This suggests a possible upside of 304.3% from the stock's current price.
View analysts price targets for LSTA or view top-rated stocks among Wall Street analysts.

How have LSTA shares performed in 2023?

Lisata Therapeutics' stock was trading at $2.53 on January 1st, 2023. Since then, LSTA shares have increased by 46.6% and is now trading at $3.71.
View the best growth stocks for 2023 here.

When is Lisata Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 28th 2023.
View our LSTA earnings forecast.

How were Lisata Therapeutics' earnings last quarter?

Lisata Therapeutics, Inc. (NASDAQ:LSTA) announced its quarterly earnings data on Thursday, November, 10th. The company reported ($1.48) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.90) by $0.58.

What is Lisata Therapeutics' stock symbol?

Lisata Therapeutics trades on the NASDAQ under the ticker symbol "LSTA."

Who are Lisata Therapeutics' major shareholders?

Lisata Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Concourse Financial Group Securities Inc. (0.00%).

How do I buy shares of Lisata Therapeutics?

Shares of LSTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Lisata Therapeutics' stock price today?

One share of LSTA stock can currently be purchased for approximately $3.71.

How much money does Lisata Therapeutics make?

Lisata Therapeutics (NASDAQ:LSTA) has a market capitalization of $29.16 million. The company earns $-27,470,000.00 in net income (profit) each year or ($12.2279) on an earnings per share basis.

How can I contact Lisata Therapeutics?

Lisata Therapeutics' mailing address is 110 ALLEN ROAD 2ND FLOOR, BASKING RIDGE NJ, 07920. The official website for the company is www.caladrius.com. The company can be reached via phone at (908) 842-0100, via email at jmenditto@caladrius.com, or via fax at 646-514-7787.

This page (NASDAQ:LSTA) was last updated on 2/7/2023 by MarketBeat.com Staff